We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




为恶性血液病免疫分型而开发的32种产品

By LabMedica International staff writers
Posted on 09 May 2011
32款新型临床流式细胞测量试剂日前开发成功,可用于恶性血液病的免疫分型。

eBioscience公司(San Diego, CA, USA; www.ebioscience.com)是一家彩色流式细胞仪试剂供应商,在良好生产规范(GMP)环境中生产临床试剂。该公司最近拓展了其抗体、荧光染料和试剂产品线,使其全面覆盖诊断、免疫、肿瘤、细胞生物学和干细胞生物学。所有产品都具有优异的信噪比和90%以上的纯度。

eBioscience公司专门为临床实验室用户开发并优化了临床流式细胞仪试剂产品线。抗体封装的体积有大有小,有助于管理精准的预算。所有尺寸的配方都是每次检验5微升,减少了试剂溶液与样本容积的比值(这对于节省宝贵的样本至关重要),从而确保高效的多色免疫分型。临床实验室所用的细胞仪名目繁多,所以要求荧光染料形式的选择也多种多样。

2011年4月2–6日于美国佛罗里达州奥兰多举行的美国癌症研究协会(AACR)第102届年会暨2011年5月于美国马里兰州巴尔的摩举行的国际细胞测量推广协会第26届大会(CYTO2011)将展示eBioscience公司齐全的临床试剂产品线。

Related Links:
eBioscience >> www.ebioscience.com
Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Pipette
Accumax Smart Series
Automatic CLIA Analyzer
Shine i9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The partnership with LLS expands access to Lucent’s non-invasive blood-based biomarker tests for early detection of cognitive diseases (photo courtesy of Adobe Stock)

New Partnership Brings Alzheimer’s Blood Biomarker Test to Community Screening Network

Lucent Diagnostics, a brand of Quanterix Corporation, has partnered with Life Line Screening (LLS) to offer Lucent’s non‑invasive, blood‑based biomarker test across the United States. Programs are... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.